Clinical Trial Update: An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating subcutaneous tocilizumab with methotrexate or as monotherapy versus MTX in moderate-to-severe rheumatoid arthritis with inadequate DMAR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED